Antithrombin III Deficiency
Antithrombin III deficiency is the thrombophilia that does not achieve therapeutic anticoagulation with heparin infusion, a condition known as heparin resistance.
Mechanism of Heparin Resistance in Antithrombin Deficiency
Heparin requires antithrombin (AT) as a cofactor to exert its anticoagulant effect 1. The drug works by binding to AT and catalyzing the inactivation of coagulation factors IIa (thrombin), Xa, IXa, XIa, and XIIa 1. When AT levels are deficient—whether congenitally or acquired—heparin cannot achieve its therapeutic anticoagulant effect regardless of dose escalation 2.
The FDA label explicitly identifies AT III deficiency as a cause of heparin resistance, noting it is "frequently encountered in fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, myocardial infarction, cancer, in postsurgical patients, and patients with antithrombin III deficiency" 2.
Clinical Definition and Recognition
Heparin resistance is practically defined as:
- Inability to achieve an ACT >300 seconds after administration of >600 U/kg heparin 3
- Requiring UFH dosages >35,000 IU/day to achieve therapeutic aPTT ranges 4
- Inability to bring aPTT (60-100 seconds) or ACT within therapeutic ranges despite high doses 5
AT deficiency should be suspected when AT activity is ≤60% 4.
Management Approach
When heparin resistance from AT deficiency is identified:
- Reduce heparin immediately to 500 IU/hour to prevent bleeding complications 4
- Administer AT concentrate or fresh-frozen plasma to raise AT activity above 80% 3, 4
- Once AT is normalized, titrate heparin to achieve therapeutic aPTT of 60-100 seconds 4
- Consider anti-Factor Xa level monitoring rather than aPTT for dose adjustment, as this may be more effective in heparin-resistant patients 5, 2
The enhanced anticoagulant effect of heparin during concurrent AT III therapy necessitates dose reduction to minimize bleeding risk 2.
Important Distinction from Other Thrombophilias
Most other thrombophilias do NOT cause heparin resistance and achieve normal therapeutic anticoagulation with heparin. The 2016 BSG-ESGE guidelines explicitly reclassified thrombophilia syndromes (including Factor V Leiden, prothrombin G20210A mutation, protein C deficiency, and protein S deficiency) as low-risk conditions that do not require special bridging considerations 6. These patients respond normally to heparin anticoagulation.
Clinical Context
Congenital AT III deficiency follows autosomal-dominant transmission with prevalence of 1 in 2,000 to 1 in 20,000, typically presenting with AT levels <50% of normal 3. Acquired AT deficiency occurs in DIC, asparaginase therapy, nephrotic syndrome, and during extracorporeal circulation, where heparin resistance incidence approaches 20% 3, 4.